Epizyme (EPZM) Misses Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. AMD
3. PLTR
4. CRWD
5. VRTX
6. DOX
7. CHKP
8. ON
9. HNGE
10. INSP

Go back to Epizyme (EPZM) Misses Q4 EPS by 4c

Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

March 1, 2022 7:00 AM EST

TAZVERIK® (tazemetostat) Net Product Revenue of $11.6 Million for 4Q 2021; $30.9 Million for FY 2021

$85 Million in Gross Proceeds Raised in January 2022 Public Offering, Combined with Recent Expense Reductions Announced Today, Extends Cash Runway into 3Q 2023

Company Engaged in Global Start-up Activities for SYMPHONY-1; Data Updates Expected Across Pipeline Programs in 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme (Nasdaq:... More